Evidence map›Paper›PMID 42211508›Full record

ArticleFrontiers in oncology2026

Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report.

Yujuan Dai, Dachao Chen, Shufeng Wu, Yuehua Geng, XianYing Chen, Nana Zhang, Xiangbin Tan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yujuan DaiDepartment of Oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
Dachao ChenDepartment of Oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
Shufeng WuDepartment of Oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
Yuehua GengDepartment of Pathology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
XianYing ChenDepartment of Oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
Nana ZhangDepartment of Gastroenterology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.
Xiangbin TanDepartment of Oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a case of metachronous double primary hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) in a 62-year-old male with occult hepatitis B virus (HBV) infection, an extremely rare entity easily misdiagnosed as iCCA recurrence, especially with an alpha-fetoprotein (AFP)-negative phenotype. The patient was initially diagnosed with stage IV iCCA (cT3N0M1) with bone metastases, receiving radiotherapy for primary and metastatic lesions, followed by 2-year sequential apatinib plus camrelizumab, achieving iCCA partial remission. At 56-month follow-up, abdominal CT detected new hepatic lesions, which pathological and immunohistochemical examinations confirmed as

Indexed as

case reporthepatitis B virushepatocellular carcinomaimmunotherapyintrahepatic cholangiocarcinomametachronous tumors

Identifiers

PMID42211508
PMCPMC13212181

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.